SCHEMBL5221738

SCHEMBL5221738

Cn1cncc1C(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)c(N)c1nnnn12

nearest known ligand 0.58

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
FNTA P49354 13/20 0.58
FNTB P49356 13/20 0.58
PGGT1B P53609 5/20 0.46
IDO1 P14902 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5225577 0.83 FNTA (0.58) FNTAFNTBPGGT1BIDO1
SCHEMBL7191102 0.83 FNTA (0.47) FNTAFNTBPGGT1BIDO1
SCHEMBL7167060 0.79 FNTA (0.47) FNTAFNTBPGGT1BIDO1
SCHEMBL7854078 0.78 IDO1 (0.46) FNTAFNTBPGGT1BIDO1
SCHEMBL13186537 0.73 FNTA (1.00) FNTAFNTB
SCHEMBL5514757 0.73 FNTA (0.80) FNTAFNTBPGGT1BIDO1
SCHEMBL5733786 0.73 FNTA (1.00) FNTAFNTB
SCHEMBL6554448 0.73 FNTA (0.41) FNTAFNTBPGGT1BIDO1
SCHEMBL168438 0.72 FNTA (0.62) FNTAFNTBPGGT1BIDO1
SCHEMBL1198369 0.72 FNTA (0.62) FNTAFNTBPGGT1BIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1815247-A2 THERAPEUTIC USE OF FARNESYLTRANSFERASE INHIBITORS AND METHODS OF MONITORING THE EFFICACY THEREOF JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-08 EP disclosed
WO-2006052718-A2 FARNESYLTRANSFERASE INHIBITORS FOR TREATING SEPSIS JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-18 WO disclosed
EP-1365763-A1 FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH ANTIESTROGEN AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 2003-12-03 EP disclosed
WO-2002064142-A1 FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH ANTIESTROGEN AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 2002-08-22 WO disclosed